Study the effect of vitamin E on renal complications induced by cisplatin

Study the effect of vitamin E on cisplatin induced nephrotoxicity

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111024007892N8

Enrollment

Registered

2018-08-02

Start date

2017-06-22

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Testicular tumor. Condition 2: Head and Neck tumor. Other male genital organs Malignant neoplasm of connective and soft tissue of head, face and neck

Interventions

Intervention 1: Intervention group: Patients will be given an E Vigel capsule (Dana Pharmacy) at a dose of 400 units daily for up to two days after completion of cisplatin treatment. Intervention 2: C

Eligibility

Sex/Gender

All

Age

6 Months to 18 Years

Inclusion criteria

Inclusion criteria: Prescribing cisplatin for the patient Patient satisfaction

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Urinalysis of KIM-1(Kidney Injuri Molecule). Timepoint: At the beginning of the study and 2 days after the end of vitamin E consumption period. Method of measurement: KIM-1 (Kidney Injuri Molecule) kit of urine sample.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactIman jafarzadeh fadaki

Mashhad University of Medical Sciences

iman.jafarzadeh13@gmail.com+98 51 3726 9021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026